The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France.
M. Gross-Goupil
Honoraria - Analysis Group
S. Oudard
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Analysis Group; Bayer; Novartis; Pfizer
A. Levy
Honoraria - Analysis Group
R. Elaidi
No relevant relationships to disclose
F. Scotte
Honoraria - Roche
M. S. Duh
Research Funding - GlaxoSmithKline
S. P. Sarda
Research Funding - GlaxoSmithKline
C. Korves
Research Funding - GlaxoSmithKline
R. Goglia
Research Funding - GlaxoSmithKline
P. Ramamurthy
Research Funding - GlaxoSmithKline
M. Neary
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
B. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Analysis Group; AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche